

## PRECISION AND FUTURE MEDICINE

### Oncological outcomes of single-port VATS

**Supplementary Table 1.** Patients' characteristics (total versus selected patients)

Characteristic	Single-port group			Multi-port group		
	Total SP (n=73)	Selected SP (n=63)	P-value	Total MP (n=154)	Selected MP (n=63)	P-value
Age (yr)	61.4±9.2	60.5±9.3	0.541	60.9±9.9	61.3±11.7	0.494
Female sex	36 (49.3)	34 (54.0)	0.590	59 (38.3)	28 (44.4)	0.404
Smoking			0.625			0.849
Never smoked	40 (54.8)	38 (60.3)		72 (46.8)	31 (49.2)	
Former smoker	22 (30.1)	15 (23.8)		67 (43.5)	25 (39.7)	
Current smoker	11 (15.1)	10 (15.9)		15 (9.7)	7 (11.1)	
Charlson comorbidity index			0.607			0.152
0	37 (50.7)	34 (54.0)		103 (66.9)	36 (57.1)	
1	16 (21.9)	15 (23.8)		30 (19.5)	14 (22.2)	
2	15 (20.5)	10 (15.9)		15 (9.7)	10 (15.9)	
3	4 (5.5)	3 (4.8)		4 (2.6)	2 (3.2)	
4	1 (1.4)	1 (1.6)		2 (1.3)	1 (1.6)	
ASA class			0.854			0.860
1	17 (23.3)	15 (23.8)		40 (26.0)	15 (23.8)	
2	54 (74.0)	47 (74.6)		105 (68.2)	45 (71.4)	
3	2 (2.7)	1 (1.6)		9 (5.8)	3 (4.8)	
FEV <sub>1</sub> , %	91.5±15.4	92.3±15.4	0.770	90.3±13.7	91.6±15.2	0.429
FEV <sub>1</sub> /FVC	74.9±8.0	75.5±7.9	0.612	74.5±9.6	74.3±9.5	0.926
Histology			0.603			0.799
Adenocarcinoma	58 (79.5)	52 (82.5)		121 (78.6)	49 (77.8)	
Squamous	9 (12.3)	8 (12.7)		29 (18.8)	10 (15.9)	
Others	6 (8.2)	3 (4.8)		4 (2.6)	4 (6.3)	
Clinical T stage			0.871			0.007
T1	53 (72.6)	45 (71.4)		77 (50.0)	43 (68.3)	
T2	18 (24.7)	16 (25.4)		58 (37.7)	18 (28.6)	
T3	2 (2.7)	2 (3.2)		16 (10.4)	2 (3.2)	
T4	0	0		3 (1.9)	0	
Clinical N stage			0.785			0.153
N0	65 (89.0)	57 (90.5)		123 (79.9)	55 (87.3)	
N1	4 (5.5)	3 (4.8)		17 (11.0)	7 (11.1)	
N2	4 (5.5)	3 (4.8)		14 (9.1)	1 (1.6)	
Clinical stage						0.014
IA	51 (70.8)	44 (69.8)		70 (45.8)	39 (61.9)	
IB	12 (16.7)	11 (17.5)		37 (24.2)	12 (19.0)	
IIA	3 (4.2)	2 (3.2)		11 (7.2)	7 (11.1)	
IIB	3 (4.2)	3 (4.8)		18 (11.8)	4 (6.3)	
III	3 (4.2)	3 (4.8)		17 (11.1)	1 (1.6)	
Previous chemotherapy	2 (2.7)	2 (3.2)	0.881	17 (11.0)	0	0.006
Previous radiotherapy	1 (1.4)	1 (1.6)	0.917	12 (7.8)	0	0.023
Conversion to MP VATS	13 (17.8)	10 (15.9)	0.765			
Conversion to thoracotomy	4 (5.5)	3 (4.8)	0.851	25 (16.2)	7 (11.1)	0.335
5-year overall survival rate (%)	88.4	89.9	0.780	80.7	86.9	0.388
5-year disease-free survival rate (%)	74.2	75.1	0.894	63.0	75.7	0.073

Values are presented as mean ± standard deviation, number (%), or percentage.

SP, single-port; MP, multi-port; ASA, American Society of Anesthesiologists; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; VATS, video-assisted thoracoscopic surgery.